Logo Logo
Hilfe
Hilfe
Switch Language to English

Schrag, A.; Hommel, A. L. A. J.; Lorenzl, S.; Meissner, W. G.; Odin, P.; Coelho, M.; Bloem, B. R.; Dodel, R.; Ferreira, Joaquim; Fabbri, Margherita; Tison, Francois; Foubert-Samier, Alexandra; Read, Joy; Meinders, Marjan; Koopmans, Raymond; Richinger, Carmen; Rosqvist, Kristina; Wittenberg, Michael und Neuser, Petra (2020): The late stage of Parkinson's-results of a large multinational study on motor and non-motor complications. In: Parkinsonism & Related Disorders, Bd. 75: S. 91-96

Volltext auf 'Open Access LMU' nicht verfügbar.

Abstract

Introduction: There is little information on the late stages of parkinsonism. Methods: We conducted a multicentre study in 692 patients with late stage parkinsonism in six European countries. Inclusion criteria were disease duration of >= 7 years and either Hoehn and Yahr stage >= 4 or Schwab and England score of 50 or less. Results: Average disease duration was 15.4 (SD 7.7) years and mean total UPDRS score was 82.7 (SD 22.4). Dementia according to MDS-criteria was present in 37% of patients. Mean levodopa equivalence dose was 874.1 (SD 591.1) mg/d. Eighty two percent of patients reported falls, related to freezing (16%) or unrelated to freezing (21% of patients) or occurring both related and unrelated to freezing (45%), and were frequent in 26%. Moderate-severe difficulties were reported for turning in bed by 51%, speech by 43%, swallowing by 16% and tremor by 11%. Off-periods occurred in 68% and were present at least 50% of the day in 13%, with morning dystonia occurring in 35%. Dyskinesias were reported by 45% but were moderate or severe only in 7%. Moderate-severe fatigue, constipation, urinary symptoms and nocturia, concentration and memory problems were encountered by more than half of participants. Hallucinations (44%) or delusions (25%) were present in 63% and were moderate-severe in 15%. The association with overall disability was strongest for severity of falls/ postural instability, bradykinesia, cognitive score and speech impairment. Conclusion: These data suggest that current treatment of late stage parkinsonism in the community remains insufficiently effective to alleviate disabling symptoms in many patients.

Dokument bearbeiten Dokument bearbeiten